Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Chloroquine (CQ) and hydroxychloroquine (HCQ) are known autophagy suppressors.
• Cancer cells often develop resistance to chemotherapy and anti-angiogenic therapies.
• Autophagy modulation is explored as a strategy to overcome treatment resistance.

Purpose of the Study:

• To review the combined application of CQ/HCQ with conventional chemotherapy drugs.
• To summarize experimental and clinical data on CQ/HCQ as adjuvant cancer therapy.
• To elucidate the molecular mechanisms underlying cancer cell response to CQ/HCQ.

Main Methods:

• Review of in vitro studies on cultured cancer cells.
• Analysis of in vivo studies using animal xenograft models.
• Examination of available clinical trial data.

Main Results:

• Most in vitro and in vivo studies indicate CQ/HCQ sensitize cancer cells to cytotoxic agents.
• Combined therapy with CQ/HCQ demonstrated increased chemotherapy potential in preclinical models.
• Clinical trial results for CQ/HCQ in cancer treatment have shown inconsistencies.

Conclusions:

• Pharmacological suppression of autophagy using CQ/HCQ is a promising strategy to enhance chemotherapy efficacy.
• Further research and development of more specific autophagy inhibitors are needed.
• Despite inconsistent clinical findings, autophagy inhibition remains a valuable therapeutic avenue in oncology.